AI Verdict
HAE has stronger fundamentals based on our AI analysis.
HALO vs HAE Fundamental Comparison
| Metric | HALO | HAE |
|---|---|---|
| Revenue | $1.4B | $987.7M |
| Net Income | $316.9M | $117.5M |
| Net Margin | 22.7% | 11.9% |
| ROE | 649.2% | 12.9% |
| ROA | 12.5% | 4.7% |
| Current Ratio | 4.66x | 1.75x |
| Debt/Equity | 43.89x | 1.34x |
| EPS | $2.56 | $2.46 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
HALO vs HAE: Frequently Asked Questions
Is HALO or HAE a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), HAE has stronger fundamentals. HALO is rated HOLD (58% confidence) while HAE is rated BUY (72% confidence). This is not investment advice.
How does HALO compare to HAE fundamentally?
HALOZYME THERAPEUTICS, INC. has ROE of 649.2% vs HAEMONETICS CORP's 12.9%. Net margins are 22.7% vs 11.9% respectively.
Which stock pays higher dividends, HALO or HAE?
HALO has a dividend yield of N/A or no dividend while HAE has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in HALO or HAE for long term?
For long-term investing, consider that HALO has HOLD rating with 58% confidence, while HAE has BUY rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about HALO vs HAE?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For HALO vs HAE, the AI consensus favors HAE based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.